Tonix Pharmaceuticals Files Q1 2025 10-Q
Ticker: TNXP · Form: 10-Q · Filed: May 12, 2025 · CIK: 1430306
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Tonix Pharma's Q1 2025 10-Q is in. Check financials for latest updates.
AI Summary
Tonix Pharmaceuticals Holding Corp. filed its 10-Q for the period ending March 31, 2025. The company reported financial results for the first quarter of 2025, detailing its assets, liabilities, and equity. Specific financial figures and operational details are presented within the filing, which was submitted on May 12, 2025.
Why It Matters
This filing provides investors with an update on Tonix Pharmaceuticals' financial health and operational status for the first quarter of 2025, crucial for understanding the company's performance and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Tonix Pharmaceuticals is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-05-12 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 2024-12-31 — Prior Year End Date (Provides a comparison point for financial performance from the previous fiscal year-end.)
Key Players & Entities
- Tonix Pharmaceuticals Holding Corp. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250512 (date) — Filing date of the report
- 26 MAIN STREET, SUITE 101 (address) — Business and mailing address
- CHATHAM, NJ 07928 (address) — Business and mailing address
FAQ
What is the total revenue for Tonix Pharmaceuticals for the quarter ended March 31, 2025?
The provided text does not explicitly state the total revenue for the quarter ended March 31, 2025.
What were the net losses or gains for the period?
The provided text does not explicitly state the net losses or gains for the period ended March 31, 2025.
What is the company's cash and cash equivalents balance as of March 31, 2025?
The provided text does not explicitly state the cash and cash equivalents balance as of March 31, 2025.
What are the primary business segments or therapeutic areas Tonix Pharmaceuticals is focused on?
The filing indicates the company operates in the 'PHARMACEUTICAL PREPARATIONS [2834]' sector, but specific therapeutic areas are not detailed in this excerpt.
When was the company formerly known as TAMANDARE EXPLORATIONS INC.?
The company changed its name from TAMANDARE EXPLORATIONS INC. on March 20, 2008.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Tonix Pharmaceuticals Holding Corp. (TNXP).